GRIFTATIN - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Serial Number
87739250
Word Mark
GRIFTATIN
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2021-07-26
Filing Date
2017-12-31
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2018-04-24
Attorney Name
Law Office Assigned Location Code
M60
Employee Name
LEVINE, HOWARD B
Statements
Goods and Services
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of orodispersable tablets and/or sublingual tablets that facilitate the delivery of pharmaceutical preparations; Nutraceuticals for use as a dietary supplement; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of the cardiovascular system, the circulatory system, the digestive system, the excretory system, the endocrine system, the integumentary system, the exocrine system, the lymphatic system, the immune system, the muscular system, the nervous system, the renal system, the urinary system, the reproductive system, and/or the skeletal system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Cardiovascular pharmaceuticals; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of the endocannabinoid; Human vaccine preparations; Oral vaccine preparations
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2018-01-16
Primary Code
005
Correspondences
Name
Samuel Fifer
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2018-01-03 | NEW APPLICATION ENTERED IN TRAM |
2018-01-16 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2018-03-22 | ASSIGNED TO EXAMINER |
2018-03-22 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2018-04-04 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2018-04-24 | PUBLISHED FOR OPPOSITION |
2018-04-24 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2018-06-19 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2018-12-19 | TEAS EXTENSION RECEIVED |
2018-12-19 | EXTENSION 1 FILED |
2018-12-19 | EXTENSION 1 GRANTED |
2018-12-21 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-01-17 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2019-01-17 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2019-05-22 | TEAS EXTENSION RECEIVED |
2019-05-22 | EXTENSION 2 FILED |
2019-05-22 | EXTENSION 2 GRANTED |
2019-05-24 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-05-22 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2019-10-15 | TEAS EXTENSION RECEIVED |
2019-10-15 | EXTENSION 3 FILED |
2019-10-15 | EXTENSION 3 GRANTED |
2019-10-17 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-06-08 | TEAS EXTENSION RECEIVED |
2020-06-08 | EXTENSION 4 FILED |
2020-06-08 | EXTENSION 4 GRANTED |
2020-06-10 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-12-08 | TEAS EXTENSION RECEIVED |
2020-12-21 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2020-12-08 | EXTENSION 5 FILED |
2021-01-04 | EXTENSION 5 GRANTED |
2021-01-05 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-07-26 | ABANDONMENT - NO USE STATEMENT FILED |
2021-07-26 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |